Pipeline Molecules1

29

Total Molecules

Phase I: 28 molecules

Phase II: 8 molecules

Phase III: 7 molecules

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Make selections below to learn more.

Click to Expand

Tumor Types
Pipeline Molecules Explorer | BioOncology

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Phase I

  • Hematologic
  • Hematologic
  • Breast

Antibody-drug conjugate
(anti-MUC16 TDC)

(RG7882)a

 

  • Gastrointestinal
  • Gynecologic

Antibody-drug conjugate
(NME ADC)

(RG7986)a

 

  • Hematologic

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Hematologic
  • Melanoma
  • Solid Tumor

BET inhibitor

(TEN-010, RG6146)b

 

  • Hematologic
  • Solid Tumor

CD20 TCB

(RG6026)

 

  • Hematologic

CD20 TDB

(RG7828)

 

  • Hematologic

Cergutuzumab amunaleukin
(CEA-IL2v)

(RG7813)

 

  • Solid Tumor

ChK1 inhibitor

(GDC-0575, RG7741)c

 

  • Hematologic
  • Solid Tumor

Cobimetinib
(MEK inhibitor)

(GDC-0973, RG7421)d

  • Breast
  • Gastrointestinal
  • Hematologic
  • Solid Tumor

Codrituzumab
(anti–glypican-3 MAb)

(GC33, RG7686)e

 

  • Gastrointestinal

Emactuzumab
(CSF-1R MAb)

(RG7155)

 

  • Solid Tumor

FAP-DR5 biMAb

(RG7386)

 

  • Solid Tumor

FAP-IL2v FP

(RG7461)

  • Genitourinary
  • Solid Tumor

Monoclonal antibody
(anti-TIGIT MAb)

(MTGI7192A, RG6058)

  • Solid Tumor

NME MAb

(RG6160)

  • Hematologic

Obinutuzumab
(anti-CD20)

(RG7159)

  • Hematologic

Pan-RAF inhibitor

(RG6185)

 

  • Solid Tumor

Personalized Cancer Vaccine

(RG6180)f

 

  • Solid Tumor

PI3K inhibitor

(RG6114, GDC-0077)

 

  • Breast
  • Solid Tumor

Raf/MEK dual inhibitor

(CHU)e

  • Solid Tumor

Selective estrogen receptor degrader

(SERD [2])

(GDC-0927/SRN-927, RG6047)g

 

  • Breast

Selicrelumab
(CD40 MAb)

(RG7876)

  • Solid Tumor

Vanucizumab
(anti–ANG2-VEGF biMAb)

(RG7221)

 

  • Gynecologic
  • Solid Tumor

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)h

  • Hematologic
Page Error

An error occurred while loading this portion of content. We are resolving this issue and apologize for the inconvenience.

Please check back soon for an update.

Phase II

  • Hematologic

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)c

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Hematologic
  • Breast

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Hematologic
  • Melanoma
  • Solid Tumor

Cobimetinib
(MEK inhibitor)

(GDC-0973, RG7421)

  • Breast

Codrituzumab
(anti–glypican-3 MAb)

(GC33, RG7686)e

 

  • Gastrointestinal

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)h

  • Hematologic

Phase III

  • Hematologic

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)c

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Hematologic
  • Breast

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Hematologic
  • Melanoma
  • Solid Tumor

Cobimetinib
(MEK inhibitor)

(GDC-0973, RG7421)d

  • Breast
  • Gastrointestinal
  • Hematologic
  • Solid Tumor

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)h

  • Hematologic

aDeveloped in collaboration with Seattle Genetics. bTesha acquisition. cDeveloped in collaboration with Array BioPharma. dDeveloped in collaboration with Exelixis. eDeveloped in collaboration with Chugai. fDeveloped in collaboration with BioNTech. gSeragon acquisition. hJoint project with AbbVie.

Reference

  1. Roche half-year results 2017 presentation. https://www.roche.com/dam/jcr:35ee4c5e-cb3d-49a5-9893-78d9757cef02/en/irp170727.pdf. Accessed September 12, 2017.